Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI

Figure 3

Time-to-event curves in patients with versus without interruption of DAPT within 12 months. (a) Major adverse cardiac and cerebrovascular events; (b) all-cause death; (c) cardiac death; (d) myocardial infarction; (e) stent thrombosis; (f) stroke; (g) BARC type 2, 3, or 5 bleeding; and (h) net adverse clinical events. Numbers at risk are shown below the chart.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)